• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Anal Biochem . Diagnostic performance of a novel antigen-capture ELISA for the detection of SARS-CoV-2

tetano

Editor, Senior Moderator
Anal Biochem


. 2023 Feb 6;115079.
doi: 10.1016/j.ab.2023.115079. Online ahead of print.
Diagnostic performance of a novel antigen-capture ELISA for the detection of SARS-CoV-2


Hamidreza Yadegari[SUP] 1 [/SUP], Mehdi Mohammadi[SUP] 1 [/SUP], Faezeh Maghsood[SUP] 1 [/SUP], Ahmad Ghorbani[SUP] 1 [/SUP], Tannaz Bahadori[SUP] 1 [/SUP], Forough Golsaz-Shirazi[SUP] 1 [/SUP], Amir-Hassan Zarnani[SUP] 1 [/SUP], Vahid Salimi[SUP] 2 [/SUP], Mahmood Jeddi Tehrani[SUP] 3 [/SUP], Mohammad Mehdi Amiri[SUP] 4 [/SUP], Fazel Shokri[SUP] 5 [/SUP]



Affiliations

Abstract

Background and aims: The coronavirus disease 2019 (COVID-19) pandemic is a serious health problem worldwide. Early virus detection is essential for disease control and management. Viral antigen detection by ELISA is a cost-effective, rapid, and accurate antigen diagnostic assay which could facilitate early viral detection.
Method: An antigen-capture sandwich ELISA was developed using novel nucleocapsid (NP)-specific mouse monoclonal antibodies (MAbs). The clinical performance of the assay was assessed using 403 positive and 150 negative respiratory samples collected during different SARS-CoV-2 variants outbreaks in Iran.
Results: The limit of detection of our ELISA assay was found to be 43.3 pg/ml for recombinant NP. The overall sensitivity and specificity of this assay were 70.72% (95% CI: 66.01-75.12) and 100% (95% CI: 97.57-100), respectively, regardless of Ct values and SARS-CoV-2 variants. There was no significant difference in our assay sensitivity for the detection of Omicron subvariants compared to Delta variant. Assay sensitivity for the BA.5 Omicron subvariant was calculated as 91.89% (95% CI: 85.17-96.23) for samples with Ct values < 25 and 82.70% (95% CI: 75.19-88.71) for samples with Ct values < 30.
Conclusion: Our newly developed ELISA method is reasonably sensitive and highly specific for detection of SARS-CoV-2 regardless of the variants and subvariants of the virus.

Keywords: COVID-19; Monoclonal antibody; Nucleocapsid; SARS-CoV-2; Sandwich ELISA.
 
Back
Top Bottom